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Scaling the bioequivalence limits 
In its more general form (Tothfalusi and Endrenyi, 2003), the method of linearly scaling 
the bioequivalence limits combines the usual model to establish ABE, based on fixed 
bioequivalence limits (BEL): 
 < ,θ φ θ− <  
with a scaled model: 
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where 
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SCσ  is a variance used as a scaling factor. In crossover two-period studies the 
scaling factor is the residual variance, 
2 2
SCσ σ= . According to a preset regulatory 
variability limit, 
2
0 ,σ  ABE is evaluated using fixed bioequivalence limits if its variance 
is not greater than 
2
0σ  and using scaled bioequivalence limits otherwise. That is, the 
scaled limits (BELsc) in the original scale are: 
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In order to avoid discontinuities in the ABE limits when taken as a function of 
2 ,SCσ  the 
regulatory variability limit σ0 and the proportionality constant k, which should have the 
form 
0 ,k θ σ=  must be adequately chosen. A possible choice is 
0 0.2,σ = recommended in the case of individual BE by the FDA guidance 
CDER(2001). Then the proportionality constant becomes ln(1.25) 0.2 1.116k = = . 
Other possibilities are σ0 = 0.22314, recommended by Boddy et al. (1995) with k = 1, or 
0 0.294σ =  (Shah et al., 1996) with k = 0.759. This last possibility corresponds to an 
ANOVA-CV threshold of 30%, that defines the condition for a high variability drug. 
In addition to the arbitrary choice of the “switching” variability, σ0, the scaling variance 
must be estimated. As a consequence, different bioequivalence limits will be calculated 
for each individual study. The decision as to whether using constant or scaled limits is 
taken on the basis of a (random) variability estimate. And obviously, for a sufficiently 
large estimated variance, bioequivalence will be declared for D  values far from the 
usual bioequivalence limits, a similar criticism to that one made to Berger and Hsu 
(1996) method. 
To alleviate the arbitrariness of these criteria, Karalis et al. (2004) developed scaled BE 
limits incorporating variability and the constraint that the estimated formulation effect 
should not greatly exceed ±223. The general form of these limits is: 
 ( )( )1 2ˆ log 1.25SCk kσ +∓  (2) 
where k1 is a proportionality factor and k2 is a “constraint” factor taking into account the 
maximum point estimate permitting ABE declaration. Different choices of k1 and k2 
                                                 
1 All numeric references to formulae correspond to this paper 
define different methods for specifying the limits, including fixed limits and scaling like 
the BELsc introduced previously. 
Among the possible choices for k1 and k2 two possibilities defining the methods labelled 
as BELscG1 and BELscG2 in Karalis et al. (2004) are: 
 
Method k1 k2 
BELscG1 (5−4exp(D )) 0.496 1 
BELscG2 (3−2 exp(D )) 0.496 (3−2 exp(D )) 
 
 More precisely: 
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ˆ2 3 2exp 0.496 log 1.25 .
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These equations are applied when 0D ≥ , otherwise D−  is used to calculate the limits.  
Additionally, Karalis et al. (2005) proposed limits scaling with variability but only up to 
a -dependentD  plateau value, combining the classic (0.80-1.25) with the FDA 
expanded (0.70-1.43) limits into a single criterion. The authors proposed three different 
functions, based on Michaelis-Menten, Exponential and Weibull type expressions: 
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where α is the parameter controlling the minimum value, β the parameter that affects 
the maximum value and γ  is the parameter that controls the rate of gradual change of 
the BE limit. A recommended choice of parameter values is α = 1.25, β = 1.33 and γ = 
4. 
A possible disadvantage of these limits is precisely its over-parameterization. They are 
based on the need for the limits to be less strict for a study with D  around zero in 
comparison to a study in which D  is close to the bioequivalence limit. Kytariolos et al. 
(2006) developed limits based only on variability considerations. They considered that 
the failure of the classic unscaled limits was due to the high producer risk as variability 
increases. Thus, scaled BE limits should incorporate the magnitude of intrasubject 
variability, levelling off as a function of this magnitude. In the original scale, the upper 
bioequivalence limit has the general form:  
 ( )lim,efbasal BEL BE s u+  
where, BEef, is known as the bioequivalence limit expansion function. The BEef is a 
function of intrasubject variability ˆSCσ , and a predefined maximum value for the upper 
limit, ulim. It affects the rate of gradual change of the limits. The basal limit is a 
minimum basal value, e.g. 1.20 or 1.25. Two model functions, the Sigmoid and the 
Weibull, were considered by the authors, giving rise to the following expressions for the 
upper limits:  
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where α is the minimum or basal value of the upper limits in the original scale (1.25 or 
1.20), β is the maximum or plateau value of the upper limit (1.43 or 1.33), and γ is a 
constant controlling the rate of gradual change of the upper limit (1 to 8 in the Sigmoid 
Model and 1 to 5 in the Weibull model). The terms CV and CV0 represent the estimated 
coefficient of variation and at the inflection point, respectively, both in the original 
scale. They are related to the corresponding variances in the logarithmic scale by means 
of (19) in Ocaña et al. (2008). 
An example of  HV drug study 
Sánchez et al. (2008) illustrate the use of the preceding methods in Furosemide data 
(Furosemide 40 mg tablets, generic, as the test formulation vs. LASIX 40 mg, Aventis
®
 
as the reference formulation) coming from a randomized 2×2 crossover trial performed 
with N = 16 healthy individuals. The ANOVA estimated coefficient of variation for 
Cmax was 36.67%, which seems to confirm that this diuretic is a HV drug with respect to 
this pharmacokinetic measure. The direct drug effect estimate for log Cmax was 
0.1599D = −  with se 0.1256
D
= . According to these values, the Schuirmann’s TOST 
procedure lower and upper p-values were 0.0043 and 0.3112, respectively. 
Bioequivalence can’t be declared due to the lack of rejection of one of the one-sided 
null hypotheses associated to the TOST procedure. Equivalently, the shortest 90% 
confidence interval is [68.3, 106.3], not included in the bioequivalence limits [80, 125]. 
A similar conclusion is reached using the 95% confidence intervals (13), (15) or (16), 
with values [68.3, 106.3], [68.3, 146.5] and [68.3, 106.3], respectively. Note also that 
there will be a similar conclusion if the widened (up to fixed values) bioequivalence 
limits [70, 143] (FDA proposal) or [75, 133] (EMEA proposal) were used. 
The arbitrariness in the choice of the proportionality constant k in the scaled limits (20) 
is illustrated by the fact that for k = 1.116, the resulting equivalence limits are [67.3, 
148.6] and bioequivalence should be declared, no matter the confidence interval type, 
while the opposite conclusion should be drawn under other possibilities (k = 1 or 0.759). 
The results with the scaled bioequivalence approach (21) are more coherent. The 
noncentral Student’s t confidence interval (23) is [−3.24, 0.39]. For k = 1.116, 1 and 
0.759 the corresponding bioequivalence limits are [−3.16, 3.16], [−2.83, 2.83] and 
[−2.15, 2.15]. Then, it is not possible to declare bioequivalence, irrespective of the 
choice of k. 
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